Dechert Advises LXO Group on Its Acquisition From Bayer of Drug Nimotop®

Dechert advised Laboratoire X.O (LXO Group), a France-based international pharmaceutical group, on the acquisition from Bayer of marketing rights for the drug Nimotop® (nimodipine) outside mainland China.

This treatment is available in more than 45 countries and prescribed for treatment of cerebral vasospasm following a cerebral hemorrhage.

Dechert’s team was led by corporate/M&A partner Ermine Bolot and health law partner Sophie Pelé, and included M&A counsel Adina Mihaescu and associate Dahila Ibourichene, Munich-based partner Carina Klaes-Staudt, health law associate Margaux Lasseigne, IP partner Olivia Bernardeau-Paupe, antitrust national partner Marion Provost and associate Lucas Leroy.

About Dechert

Dechert is a global law firm that advises asset managers, financial institutions and corporations on issues critical to managing their business and their capital – from high-stakes litigation to complex transactions and regulatory matters. We answer questions that seem unsolvable, develop deal structures that are new to the market and protect clients’ rights in extreme situations. Our 1,000+ lawyers across 21 offices globally focus on the financial services, private equity, private credit, real estate, life sciences and technology sectors.

Dechert Paris office is a key component of the firm's strategy in Europe and is active in antitrust/competition and European law, corporate and securities, financial services matters, financing, intellectual property, international arbitration, labor and employment, litigation and compliance, regulatory and tax.

Dechert’s life sciences team in France represents companies ranging from multinational giants to emerging companies involving all aspects of the life sciences industry, including pharmaceuticals, biotechnology, drug discovery, genomics, biopharmaceuticals, diagnostics, medical devices and health care. We also assist investment funds with life sciences investments. Read more »